Venlafaxine for Treatment-Resistant Unipolar Depression
The DOI matches its Crossref record.
Abstract
The purpose of this study is to evaluate the novel antidepressant venlafaxine for the management of treatment-resistant unipolar depression. We gave unblinded venlafaxine to 84 consecutive outpatients and inpatients who met DSM-III-R criteria for major depression and who had failed to respond to at least three adequate trials of antidepressants from at least two different antidepressant classes or electroconvulsive therapy, plus at least one attempt at augmentation. Patients were evaluated after a drug free period at baseline and regular intervals with the 21-item Hamilton Rating Scale for Depression (HAM-D-21), Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinical Global Impressions Scale Improvement item (CGI). Full response for each scale was defined as follows: HAM-D-21 score of 8 or lower, a MADRS score of 12 or lower, and CGI score of 1; partial responses was defined as a 50% decrease in the HAM-D and MADRS, with final scores greater than 8 and 12, respectively, and for the CGI, a score equal to 2. About a third of patients were considered to be either full or partial responders (32.9% by HAM-D-21, 30.0% by MADRS, and 40% by CGI) after 12 weeks of venlafaxine treatment. To date, about 46% of responders have sustained their response for at least 3 months after the acute response. Venlafaxine is effective for a significant, but small, minority of patients with rigorously defined triple-resistant depression; the improvement was maintained for about half of the responders for the first 3 months of maintenance therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is also some evidence that high doses of certain antidepressants (e.g. venlafaxine) 53, 89 or antipsychotics (e.g. olanzapine) 52 can be effective strategies in the management of treatment resistant depression and schizophrenia respectively.”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [89]
Citations
Cited by
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Self-citation
Metadata
- Authors
- NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J.
- Affiliations
- Harvard University (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1994-12
- Volume
- 14
- Issue
- 6
- Pages
- 419???423
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2027044241
- Cited by
- 198
- References
- 0
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 5 · 2021: 6 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- venlafaxine, treatment-resistant depression, major depressive disorder, antidepressant efficacy, maintenance therapy, augmentation therapy, electroconvulsive therapy
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Aged, Cyclohexanols, Depressive Disorder, Female, Humans, Male, Middle Aged, Personality Assessment, Personality Inventory, Treatment Outcome, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine for Treatment-Resistant Unipolar Depression. https://app.cochat.ai/papers/10.1097/00004714-199412000-00008
- The paper
- NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994). Venlafaxine for Treatment-Resistant Unipolar Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199412000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.